Anti-SLC39A13 monoclonal antibody
Pre-made anti-SLC39A13 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to SLC39A13/SLC39A13 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP1736-Ab-1/ GM-Tg-hg-IP1736-Ab-2 | Anti-Human SLC39A13 monoclonal antibody | Human |
GM-Tg-rg-IP1736-Ab-1/ GM-Tg-rg-IP1736-Ab-2 | Anti-Rat SLC39A13 monoclonal antibody | Rat |
GM-Tg-mg-IP1736-Ab-1/ GM-Tg-mg-IP1736-Ab-2 | Anti-Mouse SLC39A13 monoclonal antibody | Mouse |
GM-Tg-cynog-IP1736-Ab-1/ GM-Tg-cynog-IP1736-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SLC39A13 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP1736-Ab-1/ GM-Tg-felg-IP1736-Ab-2 | Anti-Feline SLC39A13 monoclonal antibody | Feline |
GM-Tg-cang-IP1736-Ab-1/ GM-Tg-cang-IP1736-Ab-2 | Anti-Canine SLC39A13 monoclonal antibody | Canine |
GM-Tg-bovg-IP1736-Ab-1/ GM-Tg-bovg-IP1736-Ab-2 | Anti-Bovine SLC39A13 monoclonal antibody | Bovine |
GM-Tg-equg-IP1736-Ab-1/ GM-Tg-equg-IP1736-Ab-2 | Anti-Equine SLC39A13 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP1736-Ab-1/ GM-Tg-hg-IP1736-Ab-2; GM-Tg-rg-IP1736-Ab-1/ GM-Tg-rg-IP1736-Ab-2; GM-Tg-mg-IP1736-Ab-1/ GM-Tg-mg-IP1736-Ab-2; GM-Tg-cynog-IP1736-Ab-1/ GM-Tg-cynog-IP1736-Ab-2; GM-Tg-felg-IP1736-Ab-1/ GM-Tg-felg-IP1736-Ab-2; GM-Tg-cang-IP1736-Ab-1/ GM-Tg-cang-IP1736-Ab-2; GM-Tg-bovg-IP1736-Ab-1/ GM-Tg-bovg-IP1736-Ab-2; GM-Tg-equg-IP1736-Ab-1/ GM-Tg-equg-IP1736-Ab-2 |
Products Name | Anti-SLC39A13 monoclonal antibody |
Format | mab |
Target Name | SLC39A13 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-SLC39A13 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP1736-Ag-1 | Recombinant multi-species S39AD/ SLC39A13/ EDSSPD3 protein |
ORF Viral Vector | pGMAAV000291 | house mouse Slc39a13 AAV plasmid |
ORF Viral Vector | vGMAAV000291 | house mouse Slc39a13 AAV particle |
Target information
Target ID | GM-IP1736 |
Target Name | SLC39A13 |
Gene ID | 91252,68427,295928,713420,475981,101095193,614946,100058004 |
Gene Symbol and Synonyms | 1100001L14Rik,EDSSPD3,LZT-Hs9,SCDEDS,SLC39A13,ZIP-13,ZIP13 |
Uniprot Accession | Q96H72,Q2M1K6,A5D7H1 |
Uniprot Entry Name | S39AD_HUMAN,S39AD_RAT,S39AD_BOVIN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000165915 |
Target Classification | N/A |
The target: SLC39A13, gene name: SLC39A13, also named as EDSSPD3, LZT-Hs9, SCDEDS, ZIP13. This gene encodes a member of the LIV-1 subfamily of the ZIP transporter family. The encoded transmembrane protein functions as a zinc transporter. Mutations in this gene have been associated with the spondylocheiro dysplastic form of Ehlers-Danlos syndrome. Alternate transcript variants have been found for this gene. [provided by RefSeq, Jan 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.